- Home
- TURN vs SLGL Comparison
TURN vs SLGL Comparison
Compare TURN & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TURN
- SLGL
- Stock Information
- Founded
- TURN 1981
- SLGL 1997
- Country
- TURN United States
- SLGL Israel
- Employees
- TURN N/A
- SLGL N/A
- Industry
- TURN Finance/Investors Services
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- TURN Finance
- SLGL Health Care
- Exchange
- TURN Nasdaq
- SLGL Nasdaq
- Market Cap
- TURN 39.9M
- SLGL 19.3M
- IPO Year
- TURN N/A
- SLGL 2018
- Fundamental
- Price
- TURN $4.11
- SLGL $8.14
- Analyst Decision
- TURN
- SLGL Buy
- Analyst Count
- TURN 0
- SLGL 1
- Target Price
- TURN N/A
- SLGL $40.00
- AVG Volume (30 Days)
- TURN 21.6K
- SLGL 25.4K
- Earning Date
- TURN 01-01-0001
- SLGL 08-15-2025
- Dividend Yield
- TURN N/A
- SLGL N/A
- EPS Growth
- TURN N/A
- SLGL N/A
- EPS
- TURN N/A
- SLGL N/A
- Revenue
- TURN $194,813.00
- SLGL $12,103,000.00
- Revenue This Year
- TURN N/A
- SLGL N/A
- Revenue Next Year
- TURN N/A
- SLGL $31.17
- P/E Ratio
- TURN N/A
- SLGL N/A
- Revenue Growth
- TURN 254.25
- SLGL 603.66
- 52 Week Low
- TURN $3.12
- SLGL $3.34
- 52 Week High
- TURN $4.25
- SLGL $16.50
- Technical
- Relative Strength Index (RSI)
- TURN 64.70
- SLGL 63.80
- Support Level
- TURN $3.93
- SLGL $6.96
- Resistance Level
- TURN $4.02
- SLGL $7.48
- Average True Range (ATR)
- TURN 0.07
- SLGL 0.28
- MACD
- TURN 0.01
- SLGL 0.07
- Stochastic Oscillator
- TURN 77.18
- SLGL 95.88
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.